Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

Rhea-AI Summary

Palisade Bio (NASDAQ: PALI) has announced the European Patent Office (EPO) will publish a patent covering its lead drug, LB1148, on December 22, 2021, offering protection until 2035. This patent strengthens IP protection globally, complementing existing patents in the US and other countries. The company is focused on advancing LB1148 through clinical trials aimed at treating acute and chronic gastrointestinal complications. Previous Phase 2 trials showed LB1148's safety and efficacy, indicating significant improvements in bowel function and reduced ICU stays.

Positive

• EPO patent for LB1148 grants protection until 2035, enhancing IP strength.
• Phase 2 trials demonstrated significant improvement in bowel function.
• Decrease in ICU and hospital stay lengths noted compared to placebo.

Negative

• None.

EPO expected to publish patent on December 22, 2021

CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ: PALI), a late-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the company will be granted a patent from the European Patent Office (EPO) covering its lead investigational drug product, LB1148. The patent will publish on December 22, 2021, and provide protection until 2035.

“With the European patent grant, this greatly strengthens the IP protection of our lead drug candidate LB1148 for the global pharmaceutical market. This grant builds upon the corresponding patents in the United States, China, Australia, Japan, India, Mexico, and Taiwan,” said Thomas Hallam, Ph.D., CEO of Palisade Bio. “We are continuing to strengthen patent protections for LB1148 and its uses across the globe as we advance our clinical studies with LB1148.”

About Palisade Bio.

Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, advancing towards Phase 3, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.

Forward Looking Statements
This communication contains “forward-looking” statements, including, without limitation, statements related to expectations regarding Palisade’s plans for future clinical development of LB1148, plans to continue to strengthen patent protections for LB1148 and the potential for its therapies to address health conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its clinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 . Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Palisade Bio Investor Relations Contact: 
Dawn Hofmeister
ir@palisadebio.com

Palisade Bio Media Relations Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378

FAQ

What is the significance of the patent granted to Palisade Bio for LB1148?

The patent granted by EPO for LB1148 strengthens its IP protection until 2035, enhancing the drug's market position.

When will the European Patent Office publish the patent for LB1148?

The patent for LB1148 is expected to be published on December 22, 2021.

What were the results of the Phase 2 trials for LB1148?

Phase 2 trials showed LB1148's safety, tolerability, and significant improvements in bowel function and reduced hospital stays compared to placebo.

What does the patent grant mean for Palisade Bio's future?

The patent grant supports Palisade Bio's strategy to advance LB1148 through clinical studies and enhances its competitive position in the global pharmaceutical market.